LEGEND-T2DM Evidence Dissemination Summary

Target: **dapagliflozin**, Comparator: **glimepiride** Outcome: **Diarrhea** Subgroup: **All**

How Often? (Incidence Rates from Target in PS-matched cohorts)

Data source	Persons exposed	Person-time (yrs)	Nr. of outcomes	IR (/1,000 PY)
CCAE	12,918	10,736	265	24.68
Clinformatics	4,649	2,289	82	35.82
DA Germany	4,586	3,518	9	2.56
LDP France	-	-	-	-
MDCD	982	465	21	45.15
MDCR	800	507	16	31.53
Open Claims	136,453	104,970	1,433	13.65
Optum EHR	9,317	2,116	61	28.83
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective Diagnostics from PS Matching)



What have we learned from the OHDSI Network? (composite estimates)